NASDAQ:BLUE bluebird bio Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding bluebird bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $55.67 -0.28 (-0.50 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$53.36Now: $55.67▼$56.1950-Day Range$53.18MA: $58.23▼$65.7752-Week Range$38.95Now: $55.67▼$108.15Volume678,848 shsAverage Volume1.08 million shsMarket Capitalization$3.69 billionP/E RatioN/ADividend YieldN/ABeta2.2 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; and TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 14 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $103.77, bluebird bio has a forecasted upside of 86.4% from its current price of $55.67.Amount of Analyst Coveragebluebird bio has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform Votesbluebird bio has received 1,000 “outperform” votes. (Add your “outperform” vote.)Underperform Votesbluebird bio has received 652 “underperform” votes. (Add your “underperform” vote.)Community Sentimentbluebird bio has received 60.53% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote “Outperform” if you believe BLUE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BLUE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $109,995.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions96.39% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to decrease in the coming year, from ($10.42) to ($12.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.68 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLUE Previous Symbol CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone339-499-9300Debt Debt-to-Equity RatioN/A Current Ratio8.18 Quick Ratio8.18Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$44.67 million Price / Sales82.53 Cash FlowN/A Price / Cash FlowN/A Book Value$23.22 per share Price / Book2.40Profitability EPS (Most Recent Fiscal Year)($14.31) Net Income$-789,610,000.00 Net Margins-272.66% Return on Equity-47.02% Return on Assets-36.02%Miscellaneous Employees1,090 Outstanding Shares66,223,000Market Cap$3.69 billion Next Earnings Date10/29/2020 (Estimated) OptionableOptionable $55.67 -0.28 (-0.50 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BLUE News and Ratings via Email Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. bluebird bio (NASDAQ:BLUE) Frequently Asked Questions How has bluebird bio's stock been impacted by Coronavirus (COVID-19)? bluebird bio's stock was trading at $61.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLUE stock has decreased by 9.5% and is now trading at $55.67. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of bluebird bio? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for bluebird bio. When is bluebird bio's next earnings date? bluebird bio is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020. View our earnings forecast for bluebird bio. How were bluebird bio's earnings last quarter? bluebird bio Inc (NASDAQ:BLUE) released its quarterly earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($2.58) by $2.22. The biotechnology company had revenue of $198.89 million for the quarter, compared to the consensus estimate of $101.74 million. bluebird bio had a negative net margin of 272.66% and a negative return on equity of 47.02%. View bluebird bio's earnings history. What price target have analysts set for BLUE? 18 brokerages have issued 12-month price targets for bluebird bio's stock. Their forecasts range from $68.00 to $160.00. On average, they anticipate bluebird bio's share price to reach $103.77 in the next year. This suggests a possible upside of 86.4% from the stock's current price. View analysts' price targets for bluebird bio. Who are some of bluebird bio's key competitors? Some companies that are related to bluebird bio include BioNTech (BNTX), Qiagen (QGEN), argenx (ARGX), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Repligen (RGEN), Acceleron Pharma (XLRN), Novavax (NVAX), Momenta Pharmaceuticals (MNTA), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Spark Therapeutics (ONCE) and China Biologic Products (CBPO). View all competitors. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include BioMarin Pharmaceutical (bmrn), Opko Health (OPK), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Celgene (CELG), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and Medivation (MDVN). Who are bluebird bio's key executives? bluebird bio's management team includes the following people: Mr. Nick Leschly, Pres, CEO & Director (Age 46)Mr. Jason F. Cole, Chief Operating & Legal Officer and Sec. (Age 46)Dr. Philip D. Gregory, Chief Scientific Officer (Age 48)Mr. Jeffrey T. Walsh, Chief Strategy Officer (Age 53)Dr. David M. Davidson, Chief Medical Officer (Age 55) What is bluebird bio's stock symbol? bluebird bio trades on the NASDAQ under the ticker symbol "BLUE." Who are bluebird bio's major shareholders? bluebird bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.21%), Victory Capital Management Inc. (2.75%), First Trust Advisors LP (2.10%), TimesSquare Capital Management LLC (1.68%), FMR LLC (1.24%) and Nuveen Asset Management LLC (1.10%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, Jason Cole, Jeffrey T Walsh, Joanne Smith-Farrell, Kory James Wentworth, Nick Leschly, Philip D Gregory, Susanna Gatti High and William D Baird III. View institutional ownership trends for bluebird bio. Which institutional investors are selling bluebird bio stock? BLUE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Victory Capital Management Inc., Cubist Systematic Strategies LLC, Peregrine Capital Management LLC, State of Wisconsin Investment Board, PDT Partners LLC, GAM Holding AG, and SG Americas Securities LLC. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, David Davidson, Joanne Smith-Farrell, Kory James Wentworth, Nick Leschly, Philip D Gregory, and William D Baird III. View insider buying and selling activity for bluebird bio. Which institutional investors are buying bluebird bio stock? BLUE stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., First Trust Advisors LP, Alyeska Investment Group L.P., Frontier Capital Management Co. LLC, Anchor Capital Advisors LLC, Nuveen Asset Management LLC, Candriam Luxembourg S.C.A., and TimesSquare Capital Management LLC. View insider buying and selling activity for bluebird bio. How do I buy shares of bluebird bio? Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is bluebird bio's stock price today? One share of BLUE stock can currently be purchased for approximately $55.67. How big of a company is bluebird bio? bluebird bio has a market capitalization of $3.69 billion and generates $44.67 million in revenue each year. The biotechnology company earns $-789,610,000.00 in net income (profit) each year or ($14.31) on an earnings per share basis. bluebird bio employs 1,090 workers across the globe. What is bluebird bio's official website? The official website for bluebird bio is www.bluebirdbio.com. How can I contact bluebird bio? bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
